Abstract
Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.
Keywords: Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Biologic Agents for Treatment of Rheumatoid Arthritis
Volume: 9 Issue: 1
Author(s): Bulent Butun
Affiliation:
Keywords: Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab
Abstract: Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.
Export Options
About this article
Cite this article as:
Butun Bulent, Biologic Agents for Treatment of Rheumatoid Arthritis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711692
DOI https://dx.doi.org/10.2174/187152310790711692 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TLR Signaling Pathways: Opportunities for Activation and Blockade in Pursuit of Therapy
Current Pharmaceutical Design Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Editorial [Hot Topic: Modulation and New Mediators in Inflammation Executive (Guest Editor: Frank A. Redegeld)]
Current Pharmaceutical Design Synthesis and Anti-Inflammatory Activity of Fused 1,2,4-triazolo-[3,4-b] [1,3,4]thiadiazole Derivatives of Phenothiazine
Letters in Drug Design & Discovery Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9
Combinatorial Chemistry & High Throughput Screening The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Dapagliflozin Protects H9c2 Cells Against Injury Induced by Lipopolysaccharide via Suppression of CX3CL1/CX3CR1 Axis and NF-κB Activity
Current Molecular Pharmacology Impact of COVID-19 Infection on Maternal and Neonatal Outcomes: A Review of 11078 Pregnancies Reported in the Literature
Current Women`s Health Reviews Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy EPA and DHA Differentially Affect In Vitro Inflammatory Cytokine Release by Peripheral Blood Mononuclear Cells from Alzheimer’s Patients
Current Alzheimer Research Pyrazine Functionalized Ag(I) and Au(I)-NHC Complexes are Potential Antibacterial Agents
Current Medicinal Chemistry Thymoquinone Shows the Diverse Therapeutic Actions by Modulating Multiple Cell Signaling Pathways: Single Drug for Multiple Targets
Current Pharmaceutical Biotechnology Other Activities
Current Bioactive Compounds Gold Salts Therapy in Respiratory Diseases
Current Respiratory Medicine Reviews Inflammation and Arterial Hypertension: From Pathophysiological Links to Risk Prediction
Current Medicinal Chemistry Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design HCV and Autoimmunity in Rheumatic Diseases
Current Rheumatology Reviews Hemophagocytic Lymphohistiocytosis (HLH): An Update
Current Immunology Reviews (Discontinued) High-Resolution CT Imaging Findings of Collagen Vascular Disease- Associated Interstitial Lung Disease
Current Respiratory Medicine Reviews The Senescent Mesenchymal Stem Cells in Systemic Lupus Erythematosus
Current Signal Transduction Therapy